Less impact on markers of renal function across populations¹

48 & 96 Weeks

DESCOVY^® had less long-term impact on markers of renal function vs FTC/TDF^1,2

Median change in eGFR_CG through Week 96

There was a 4.1 mL/min difference between DESCOVY FOR PrEP^® (+3.7 mL/min) and FTC/TDF (-0.4 mL/min) in eGFR_CG at Week 96.²

The long-term clinical significance of changes in eGFR is not known.

Lower serum creatinine levels were also seen with DESCOVY FOR PrEP through Week 96

Median serum creatinine decrease 0.02 mg/dL with DESCOVY FOR PrEP vs a 0.01 mg/dL decrease with FTC/TDF from baseline at Week 96
DESCOVY FOR PrEP can be used in people with impaired renal function of CrCl ≥30 mL/min

144 Weeks

eGFR remained steady over 144 weeks with DESCOVY^®2,3

Analysis of eGFR from baseline to ≥144 weeks (DESCOVY)

Median change in eGFR

The long-term clinical significance of changes in eGFR is not known.

Participants ≥50

DESCOVY^® had less long-term impact on eGFR in participants ≥50 years of age^2,4

Results were seen in participants of an age group that may already be experiencing age-associated declines

Median change in eGFR_CG in participants ≥50 years of age through Week 96

There was a 4.4 mL/min difference between DESCOVY FOR PrEP^® (+1.2 mL/min) and FTC/TDF (-3.2 mL/min) in eGFR_CG at Week 96.⁴

The long-term clinical significance of changes in eGFR is not known.

DESCOVY^® had less long-term impact on markers of renal function vs FTC/TDF^1,2

Median change in eGFR_CG through Week 96

Graph displaying DESCOVY® (emtricitabine/tenofovir alafenamide) and FTC/TDF (emtricitabine/tenofovir disoproxil fumarate). Median change in eGFR through week 96. See BOXED WARNING.

The long-term clinical significance of changes in eGFR is not known.

Lower serum creatinine levels were also seen with DESCOVY FOR PrEP through Week 96

Median serum creatinine decrease 0.02 mg/dL with DESCOVY FOR PrEP vs a 0.01 mg/dL decrease with FTC/TDF from baseline at Week 96
DESCOVY FOR PrEP can be used in people with impaired renal function of CrCl ≥30 mL/min

eGFR remained steady over 144 weeks with DESCOVY^®2,3

Analysis of eGFR from baseline to ≥144 weeks (DESCOVY)

Median change in eGFR

The long-term clinical significance of changes in eGFR is not known.

DESCOVY^® had less long-term impact on eGFR in participants ≥50 years of age^2,4

Results were seen in participants of an age group that may already be experiencing age-associated declines

Median change in eGFR_CG in participants ≥50 years of age through Week 96

The long-term clinical significance of changes in eGFR is not known.

Resource

Renal Risk Factor Brochure

A resource with information about why renal function is an important consideration when prescribing PrEP medication. Includes risk factors that may impact renal function.

Download

DESCOVY FOR PrEP^® can be used in people with impaired renal function of CrCl ≥30 mL/min.²

BMD=bone mineral density; CrCl=creatinine clearance; eGFR_CG=estimated glomerular filtration rate (Cockcroft-Gault); FTC/TDF=emtricitabine/tenofovir disoproxil fumarate; Q1, Q3=first quartile, third quartile.

You may also be interested in:

INDICATION & LIMITATION OF USE

DESCOVY^® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP^® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

INDICATION & LIMITATION OF USE

Limitation of Use: DESCOVY FOR PrEP^® is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Less impact on markers of renal function across populations1

DESCOVY® had less long-term impact on markers of renal function vs FTC/TDF1,2

Median change in eGFRCG through Week 96

The long-term clinical significance of changes in eGFR is not known.

eGFR remained steady over 144 weeks with DESCOVY®2,3

Analysis of eGFR from baseline to ≥144 weeks (DESCOVY)

Median change in eGFR

The long-term clinical significance of changes in eGFR is not known.

DESCOVY® had less long-term impact on eGFR in participants ≥50 years of age2,4

Results were seen in participants of an age group that may already be experiencing age-associated declines

Median change in eGFRCG in participants ≥50 years of age through Week 96

The long-term clinical significance of changes in eGFR is not known.

DESCOVY® had less long-term impact on markers of renal function vs FTC/TDF1,2

Median change in eGFRCG through Week 96

The long-term clinical significance of changes in eGFR is not known.

eGFR remained steady over 144 weeks with DESCOVY®2,3

Analysis of eGFR from baseline to ≥144 weeks (DESCOVY)

Median change in eGFR

The long-term clinical significance of changes in eGFR is not known.

DESCOVY® had less long-term impact on eGFR in participants ≥50 years of age2,4

Results were seen in participants of an age group that may already be experiencing age-associated declines

Median change in eGFRCG in participants ≥50 years of age through Week 96

The long-term clinical significance of changes in eGFR is not known.

DESCOVY FOR PrEP® can be used in people with impaired renal function of CrCl ≥30 mL/min.2

You may also be interested in:

This site is intended for US healthcare professionals

I am a healthcare professional

I am a patient or caregiver

Impact of PrEP on new HIV diagnoses

Contents

Transcript

Introduction

PrEP: An effective HIV prevention strategy

Regional disparities in PrEP uptake and HIV diagnoses

Normalizing PrEP use

PrEP: A potential gateway to routine care

Helping end the HIV epidemic

Introduction [0:02]

PrEP: An effective HIV prevention strategy [0:17]

Regional disparities in PrEP uptake and HIV diagnoses [1:10]

Normalizing PrEP use [1:50]

PrEP: A potential gateway to routine care [2:38]

Helping end the HIV epidemic [3:08]

PrEP use in the Black community

Contents

Transcript

Introduction

PrEP use is lowest amongst Black MSM and transgender women

Helping to support PrEP uptake in the Black community

Raising awareness of programs that increase access to HIV prevention

Reframing HIV prevention and emphasizing its importance to sexual health

Introduction [0:02]

PrEP use is lowest amongst Black MSM and transgender women [0:24]

Helping to support PrEP uptake in the Black community [1:19]

Raising awareness of programs that increase access to HIV prevention [2:20]

Reframing HIV prevention and emphasizing its importance to sexual health [3:07]

PrEP use in the Latinx/o community

Contents

Transcript

Introduction

The Latinx/o community has low PrEP uptake despite high rates of HIV diagnoses

The impact of cultural perceptions and sex in the Latinx/o community

Creating a safe space is the first step in initiating sexual health conversations

Addressing barriers to PrEP uptake in Latinx/o communities

Representation is crucial to increasing PrEP use in the Latinx/o community

Introduction [0:02]

The Latinx/o community has low PrEP uptake despite high rates of HIV diagnoses [0:24]

The impact of cultural perceptions and sex in the Latinx/o community [0:58]

Creating a safe space is the first step in initiating sexual health conversations [1:58]

Addressing barriers to PrEP uptake in Latinx/o communities [2:50]

Representation is crucial to increasing PrEP use in the Latinx/o community [4:20]

PrEP use in young MSM

Contents

Transcript

Introduction

HIV diagnoses and PrEP use in young MSM

Approaching sexual health conversations with young MSM

Engaging young MSM in HIV prevention conversations

An opportunity to connect with young individuals

Introduction [0:02]

Less impact on markers of renal function across populations¹

DESCOVY^® had less long-term impact on markers of renal function vs FTC/TDF^1,2

Median change in eGFR_CG through Week 96

eGFR remained steady over 144 weeks with DESCOVY^®2,3

DESCOVY^® had less long-term impact on eGFR in participants ≥50 years of age^2,4

Median change in eGFR_CG in participants ≥50 years of age through Week 96

DESCOVY^® had less long-term impact on markers of renal function vs FTC/TDF^1,2

Median change in eGFR_CG through Week 96

eGFR remained steady over 144 weeks with DESCOVY^®2,3

DESCOVY^® had less long-term impact on eGFR in participants ≥50 years of age^2,4

Median change in eGFR_CG in participants ≥50 years of age through Week 96

DESCOVY FOR PrEP^® can be used in people with impaired renal function of CrCl ≥30 mL/min.²

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR PrEP^® IN UNDIAGNOSED EARLY HIV‑1 INFECTION and POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B

BOXED WARNING: RISK OF DRUG RESISTANCE WITH USE OF DESCOVY FOR PrEP^® IN UNDIAGNOSED EARLY HIV‑1 INFECTION and POST-TREATMENT ACUTE EXACERBATION OF HEPATITIS B